

Clinical trials of vildagliptin monotherapy

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
vildagliptin monotherapy vs acarbose			
Pan , 2008 [NCT00110240] n=441/220 follow-up: 24 weeks	vildagliptin (100 mg daily, given as 50 mg twice daily) versus acarbose (up to 300 mg daily, given as three equally divided doses)	drug-naive patients with Type 2 diabetes	double-blind
vildagliptin monotherapy vs gliclazide			
Foley , 2009 [NCT00102388] n=NA follow-up: 2 years	monotherapy with vildagliptin 50 mg bid versus gliclazide up to 320 mg/day	drug-naive patients with type 2 diabetes	double-blind
vildagliptin monotherapy vs placebo			
Ahren , 2009 [NCT00390520] n=NA follow-up:	vildagliptin (100 mg/d) versus placebo	drug-naive patients with type 2 diabetes	Cross over
Dejager [1] , 2007 [NCT00099905] n=NA follow-up: 24 weeks	vildagliptin 50 mg or 100 mg daily versus placebo	drug-naive patients with type 2 diabetes	double-blind
Foley , 2011 <i>unpublished</i> [NCT00260156] n=29/30 follow-up:	vildagliptin 100 mg versus placebo	drug-naive patients with type 2 diabetes and mild hyperglycaemia	
Kikuchi , 2009 n=NA follow-up:	vildagliptin 50mg bid versus placebo	Japanese patients with type 2 diabetes mellitus	Japan
Pi-Sunyer , 2007 [NCT00120536] n=NA follow-up: 24 weeks	vildagliptin 50 mg or 100 mg daily, imaged versus placebo	drug-naive patients with type 2 diabetes	double-blind

continued...

Trial	Treatments	Patients	Trials design and methods
Pratley , 2006 n=70/28 follow-up:	vildagliptin 25mg bid versus placebo	-	double-blind
Ristic , 2005 n=NA follow-up:	vildagliptin 25mg or 50mg or 100mg daily versus placebo	-	
vildagliptin monotherapy vs pioglitazone			
Rosenstock** (vilda vs pio) , 2007 [NCT00101803] n=NA follow-up:	vildagliptin 100 mg daily daily versus pioglitazone 30 mg dailyaily	drug-naive patients with type 2 diabetes	double-blind

More details and results :

- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- insulin secretagogues - DPP-4 inhibitors for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q550>

2

References

Pan, 2008:

Pan C, Yang W, Barona JP, Wang Y, Niggl M, Mohideen P, Wang Y, Foley JE Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008;25:435-41 [18341596] 10.1111/j.1464-5491.2008.02391.x

Foley, 2009:

Foley JE, Sreenan S Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res 2009;41:905-9 [19705345] 10.1055/s-0029-1234042

Ahren, 2009:

Ahrn B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M, Foley JE Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009 Apr;94:1236-43 [19174497]

Dejager [1], 2007:

Dejager S, Razac S, Foley JE, Schweizer A Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007;39:218-23 [17373638] 10.1055/s-2007-970422

Foley, 2011:

unpublished

Foley JE, Bunck MC, Miller-Goede DL, Poelma M, Nijpels G, Eekhoff EM, Schweizer A, Heine RJ, Diamant M Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 2011;54:1985-91 [21547496] 10.1007/s00125-011-2167-8

Kikuchi, 2009:

Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract* 2009;83:233-40 [[19118913](#)] [10.1016/j.diabres.2008.10.006](#)

Pi-Sunyer, 2007:

Pi-Sunyer FX, Schweizer A, Mills D, Dejager S Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. *Diabetes Res Clin Pract* 2007;76:132-8 [[17223217](#)] [10.1016/j.diabres.2006.12.009](#)

Pratley, 2006:

Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. *Horm Metab Res* 2006;38:423-8 [[16823726](#)] [10.1055/s-2006-944546](#)

Ristic, 2005:

Ristic S, Byiers S, Foley J, Holmes D Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. *Diabetes Obes Metab* 2005;7:692-8 [[16219012](#)] [10.1111/j.1463-1326.2005.00539.x](#)

Rosenstock (vilda vs pio), 2007:**

Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. *Diabetes Obes Metab* 2007;9:175-85 [[17300593](#)] [10.1111/j.1463-1326.2006.00698.x](#)

Entry terms: vildagliptin, vildagliptin, (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile, NVP-LAF237, Galvus,